Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-108427
Filing Date
2025-08-14
Accepted
2025-08-14 07:33:33
Documents
74
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q lxeo-20250630.htm   iXBRL 10-Q 3137397
2 EX-10.3 lxeo-ex10_3.htm EX-10.3 29099
3 EX-31.1 lxeo-ex31_1.htm EX-31.1 14633
4 EX-31.2 lxeo-ex31_2.htm EX-31.2 14454
5 EX-32.1 lxeo-ex32_1.htm EX-32.1 7600
6 EX-32.2 lxeo-ex32_2.htm EX-32.2 7615
7 GRAPHIC img130478896_0.jpg GRAPHIC 36921
8 GRAPHIC img130478896_1.jpg GRAPHIC 24709
  Complete submission text file 0000950170-25-108427.txt   11412894

Data Files

Seq Description Document Type Size
9 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT lxeo-20250630.xsd EX-101.SCH 1518510
77 EXTRACTED XBRL INSTANCE DOCUMENT lxeo-20250630_htm.xml XML 1913694
Mailing Address 345 PARK AVENUE SOUTH FLOOR 6 NEW YORK NY 10010
Business Address 345 PARK AVENUE SOUTH FLOOR 6 NEW YORK NY 10010 (212) 547-9879
Lexeo Therapeutics, Inc. (Filer) CIK: 0001907108 (see all company filings)

EIN.: 854012572 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41855 | Film No.: 251214361
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)